Senolytic CAR T cells vs Senolytic vaccine (anti-GPNMB)
Written by Aaron CuhaReviewed Sep 2026
The short answer
Two immune system approaches to clearing old worn out cells: lab changed T cells against a vaccine. Every result for both is in mice. No human trial of either for ageing or worn out cells is registered anywhere.
- Senolytic CAR T cells people
- 0
- Senolytic CAR T cells nulls
- 0
- Senolytic vaccine (anti-GPNMB) people
- 0
- Senolytic vaccine (anti-GPNMB) nulls
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
3 animal studies, no human study
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
3 animal studies, no human study
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
Senolytic CAR T cellsSenolytic chimeric antigen receptor T cells directed at uPAR
Living immune cells, called T cells, engineered to find and kill worn-out 'zombie' cells by a marker on their surface called uPAR. Every result is in mice. No human study of this for ageing or zombie cells is registered anywhere.
Column B
Senolytic vaccine (anti-GPNMB)Senolytic vaccination against glycoprotein nonmetastatic melanoma protein B (GPNMB)
A vaccine that trains the immune system to attack GPNMB, a protein found in high amounts on worn-out 'zombie' cells. In mice it removed cells carrying GPNMB and helped male mice bred to age too fast live longer. There is no human study.
Side by side, on the facts we can check
| What we compare | Senolytic CAR T cells | Senolytic vaccine (anti-GPNMB) |
|---|---|---|
| Category | Immune | Immune |
| FDA status | No CAR T product that clears worn-out (senescent) cells is approved, and none is in a registered human trial for ageing or worn-out cells. CAR T therapy in general is approved in the United States for certain blood cancers. That is a different target, a different patient and a different weighing of risk. | Not approved anywhere and not in any registered human trial. It is a result in mice, published in a scientific journal, not a product. |
| Half-life | Not applicable in the usual sense. This is a living cell product that expands on meeting its target and persists, so exposure is governed by the survival of the engineered cells rather than by drug clearance. | Not applicable. A vaccine is dosed as a course and its effect depends on the immune response it raises, not on clearance of the injected material. |
| Molecular weight | Not reported | Not reported |
| How it works | uPAR is a protein anchored on the outside of cells. It goes up a lot when cells turn into zombie cells, so it can serve as a tag for them. A CAR is a man-made protein spliced into a T cell. It lets the T cell spot that tag directly and kill whatever carries it. Because the killer is a living cell that multiplies when it meets its target, one dose could in theory keep working. That is the big difference from a pill the body clears in hours. The same thing is the risk. An immune cell tuned to a tag that healthy tissue also carries, at lower levels, does not stop when the zombie cells are gone. | GPNMB is a protein that pokes through the cell wall and is found in high amounts on zombie cells. That makes it a tag the immune system can be trained to spot. The vaccine raises antibodies and immune cells against GPNMB, so the body clears cells that carry it, instead of a drug doing it. The appeal is that the killing uses machinery the body already has. Immune memory could, in theory, keep clearing new zombie cells long after one course of shots. The catch, shown by the same team: GPNMB itself helps zombie cells survive by protecting their lysosomes. So the target is not just a harmless flag. |
| Studies in people | 0 | 0 |
| Evidence | Animal or lab only: 3 animal studies, no human study | Animal or lab only: 3 animal studies, no human study |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Senolytic CAR T cells and Senolytic vaccine (anti-GPNMB)?
Senolytic CAR T cells: Living immune cells, called T cells, engineered to find and kill worn-out 'zombie' cells by a marker on their surface called uPAR. Every result is in mice. No human study of this for ageing or zombie cells is registered anywhere. Senolytic vaccine (anti-GPNMB): A vaccine that trains the immune system to attack GPNMB, a protein found in high amounts on worn-out 'zombie' cells. In mice it removed cells carrying GPNMB and helped male mice bred to age too fast live longer. There is no human study.
Which has stronger research evidence, Senolytic CAR T cells or Senolytic vaccine (anti-GPNMB)?
Each compound gets a band worked out from facts we counted, with the math shown. Senolytic CAR T cells is Animal or lab only (3 animal studies, no human study). Senolytic vaccine (anti-GPNMB) is Animal or lab only (3 animal studies, no human study). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Senolytic CAR T cells and Senolytic vaccine (anti-GPNMB) FDA-approved?
Senolytic CAR T cells: No CAR T product that clears worn-out (senescent) cells is approved, and none is in a registered human trial for ageing or worn-out cells. CAR T therapy in general is approved in the United States for certain blood cancers. That is a different target, a different patient and a different weighing of risk.. Senolytic vaccine (anti-GPNMB): Not approved anywhere and not in any registered human trial. It is a result in mice, published in a scientific journal, not a product..
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.